comprehensive -WSS

comprehensive

author：hotspot 2025-10-01 21:47:55 - browse：98

Alex Hogan/STAT

The J.P. Morgan Healthcare Conference is upon us, bringing its frenetic meetings, crowded hallways, and hotel rooms so expensive that even the pharmaceutical industry complains about what a free market does to the prices of scarce goods.

This year’s iteration, starting Monday in San Francisco, finds the biotech industry, in particular, in a curious spot. After a volatile 2023 that saw biotech stocks hit five-year lows in the fall, the sector had a bull run in the final weeks of the year, spurred by some high-dollar merger agreements and a prevailing sense that the macroeconomic winds were finally shifting in biotech’s direction.

Meanwhile, companies selling digital health services like telemedicine, health plans for virtual care, and AI tools for payers face a crucial year as they scramble to make good on profitability projections. Those companies, along with the country’s most powerful health systems, are seriously exploring AI, even ChatGPT, to help them meet financial milestones.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： Life sciences deals on track to hit lowest point since 2017

hotspot

WSS

Diabetes management: Digital health tools fall short, study says

How doctors and nurses shape Google's AI

Medicare Advantage insurers pressure Biden for bigger payments

What Kate Middleton's cancer revelation might teach the world

Medicare Advantage insurers pressure Biden for bigger payments

Novo Nordisk to buy Cardior, building up pipeline of heart drugs

focus

comprehensive

hotspot

Anesthesiologist group: stop taking Ozempic before surgery

Yancopoulos of Regeneron works to expand Dupixent success

Medical leaders decry Supreme Court decision on affirmative action

Diabetes management: Digital health tools fall short, study says

Medical records are filled with copy

Akero's treatment for NASH falls short in cirrhosis study

Psychedelics group wrestles with new pharma identity

Pfizer, Moderna say biotech, pharma drug development is a sprint

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

'Patient friction coefficient' can gauge a clinical trial's patient burden

Wikipedia

Testing GLP

Female surgeons have lower rates of long

STAT Readout: Today's biotech news includes Sana and Amylyx

Yancopoulos of Regeneron works to expand Dupixent success

How clinical AI models' predictive power can degrade over time

Ibogaine psychedelic therapy for opioid addiction unlikely, official says

Wikipedia

hotspot

leisure time

knowledge